Categories
2021 COVID-19 Vaccine

Breakthrough

As more Americans are receiving COVID vaccinations, there are reports of COVID occurring in individuals who have been fully vaccinated.  Can this really happen?

Yes, you may still become sick from a SARS-CoV-2 infection even if more than two weeks have passed since your final vaccine injection.  “Breakthrough” is the term for this type of infection, and many state health departments have reported breakthrough infections.  According to current CDC reports, over 50 million Americans have been fully vaccinated, accounting for 15.1% of the total U.S. population, yet 7-day rolling averages for new COVID-19 cases and hospital admissions for COVID are up 6.7% and 2.6% respectively.

We know that breakthrough infections occur with other vaccines.  In years past, many patients were admitted to the hospital for flu even though they received a flu vaccine earlier in the season.  We may be seeing a similar phenomenon with the COVID vaccine.  Furthermore, we still do not know whether most breakthrough infections are caused by the original SARS-CoV-2 virus, or one of the emerging variants.  It is possible that vaccine is less effective against one or more variants.

We have a lot to learn about breakthrough infections, but this much is clear: the pandemic is not over, and the vaccine is not a panacea.  While vaccine may provide an added layer of protection against dying from COVID, it does not prevent contraction of disease.  For now we must continue to do what we know keeps us safe: mask in public and keep apart, even if you have received a vaccine.

Categories
2021 COVID-19 Testing Vaccine

New Variant Classification

Last week the CDC revised its classifying terminology for SARS-CoV-2 variants.  To have clarity in our thoughts and debates, we must be precise in our language.  Poor decisions often descend from muddled and incomplete understandings.  I know that readers of these posts strive to be current in models of understanding and language, so they will not be caught flatfooted in conversation and reasoning.  That’s why I summarize the essential points here.

There are now three types of SARS-CoV-2 variants: Variants of Interest, Variants of Concern and Variants of High Concern.  I will discuss the definitions, lists of variants and their characteristics in reverse order.

Variants of High Concern.  Variants of high concern are those SARS-CoV-2 variants that cannot be detected by tests, are not treatable by current therapies or for which natural or vaccine induced immunity offers no protection.  Any one of those three criteria is enough to place the variant on the High Concern list.  Scary stuff.  The good news is that there are no variants on this list.  At least not yet.

Variants of Concern.  Variants of Concern have reduced detection by tests, reduced response to therapy, reduced immune protection, greater transmissibility, or more severe disease.  Again, any one of these criteria is enough to land a variant on this list.  The bad news is that the number of variants on this list has exploded since the last time I wrote about it.  In addition to the B.1.1.7 variant first detected in the UK last fall, four other variants have been added to the list:

These Variants of Concern have all been identified in the United States.  The B.1.427/429 Variants of Concern are most prevalent in the western United States, now responsible for more than half of infections in California.  The B.1.1.7 Variant of Concern is most prevalent in New Jersey and Florida, approaching 10% of the new viral infections there.  Click here to view the current numbers and distribution in the United States.  To see worldwide cases of COVID-19 caused by variants, click here.  These maps are updated at least weekly.

Variants of Interest.  Variants of Interest are being watched closely because they have the potential to become Variants of Concern based in the mutations within the variant, even though they don’t fulfill criteria to be a Variant of Concern based on observation.  This may be because the variant is too new or because too few of the instances of the variant exists to make meaningful observations.  The current Variants of Interest and their potential, but not observed, effects are listed below:

Like the Variants of Concern, all the Variants of Interest are currently present in the United States.  

There are a number of other variants which have been identified and named, but which have not yet been classified as a Variant of Interest, Variant of Concern, or Variant of High Concern.  Expect the members of these variant classification lists to change and shift as more becomes known about variants.

Categories
2021 COVID-19 Vaccine

New Guidance for the Fully Vaccinated

Yesterday, the CDC published new guidance for fully vaccinated individuals.  In this article, we will summarize the key points of this new guidance.

First, we must understand what it means to be fully vaccinated.  The full effect of vaccine-induced immunity takes about 2 weeks, so an individual is considered fully vaccinated 14 days after the final vaccine injection.  The final vaccine injection is the second dose of the Pfizer or Moderna vaccine, or the single dose of the Janssen vaccine.

Last month, the CDC issued guidance lifting the quarantine requirements for fully vaccinated individuals following a COVID exposure, provided they remain asymptomatic.  Previously, this permission expired after 90 days.  Yesterday, the CDC affirmed its previous guidance, but lifted the 90-day expiration.  According to current CDC guidance, there is no longer an outer time-limit for the benefit of vaccine-induced immunity.  This is bound to change; we will follow closely.

To the removal of quarantine requirement, the CDC also added two additional liberties yesterday: (1) fully vaccinated individuals may visit indoors with other fully vaccinated individuals without wearing masks or social distancing, and (2) fully vaccinated individuals may visit with unvaccinated people from a single household who are at low risk for COVID-19 without wearing masks or social distancing.

Other COVID precautions remain in force for fully vaccinated individuals, including masking and social distancing in public except in the specific situations mentioned above.  If symptoms develop, fully vaccinated individuals should follow the same quarantine and testing recommendations of unvaccinated individuals.

Categories
2021 COVID-19 Vaccine

New Vaccine

There were a couple of big changes in the COVID vaccine landscape last week.   On Thursday, February 25, the FDA reissued its EUAs for the Pfizer and Moderna COVID-19 vaccines, revising portions of their original EUAs.  On Saturday, February 27, the FDA issued a new EUA for the Janssen COVID-19 vaccine, commonly known as the Johnson and Johnson vaccine.  Lots of news, too much for one blog.  Let’s address the important information one bite at a time, starting with the Janssen vaccine.

Like all other COVID-19 vaccines, the Janssen vaccine has not been approved for use by the FDA.  Instead, these vaccines are authorized for use in the U.S.  This authorization is based on the FDA’s authority to make unapproved products available during an emergency when “there are no adequate, approved, and available alternatives.”  As stated in the EUA letter issued February 27, 2021, “It is an investigational vaccine not licensed for any indication.”  This means that clinical trails on vaccine safety and effectiveness have not been completed. Expect comprehensive analysis of clinical trials this summer at the earliest.

However, the Janssen vaccine differs from the other two vaccines in important ways.  First, it is not an mRNA vaccine.  Rather, it is a recombinant vector vaccine.  This vaccine is made by inserting genetic code for a protein of the target into a harmless virus (the “vector”).  When injected, this harmless virus presents the target proteins to the immune system, causing formation of antibodies, in this case antibodies to the spike proteins on the SARS-CoV-2 capsule.  This technology is not entirely new.  Manufactured (or “recombinant”) genetic code has been used to synthesize proteins for vaccines for nearly a decade.  Recombinant flu vaccines received FDA approval in 2013.  You may have received a recombinant flu vaccine in recent years. The difference between recombinant protein vaccine and viral vector vaccines has to do with where the antigenic proteins are made–either in your body (viral vector) or outside your body (recombinant protein). The harmless virus (the “viral vector”) cannot replicate within your body, so the effect is the same.

There are more differences. According to data submitted to the FDA, the Janssen vaccine is less effective preventing moderate to severe COVID-19 than the Moderna and Pfizer vaccines.  The Janssen vaccine requires only one doses compared to the two doses required by Moderna and Pfizer.  Storage of the Janssen vaccine is easier to accomplish than the other two. Vaccines features are compared as follows:

PfizerModernaJanssen
Vaccine TechnologymRNAmRNARecombinant Vector
FDA ApprovalNoNoNo
Effective rate95%95%66%
Minimum Age16 years18 years18 years
Doses221
Storage-70°C-70°CRefrigerated
Time between doses3 weeks1 monthNot applicable
Current comparison among authorized COVID-19 vaccines.

There is another difference.  In its reissued EUA, the FDA has required Pfizer to disclose post-authorization adverse events in its fact sheet to health care providers.  We will discuss that next time.

Categories
2021 COVID-19 Science Vaccine

mRNA Vaccines

To understand how mRNA vaccines work, we must first have a basic understanding of cells and genetics.  Zzzzzzz.  Wait!  Before you go to sleep, we’re going to make this really short and really simple.  Cells are bags of jelly—jellybeans, so to speak—and in those jellybeans is a kernel called a nucleus.  DNA lives in the nucleus, and like the cell’s hard drive, DNA stores and preserves the cell’s genetic code.  Genetic code is a series of nitrogen bases strung together to form nucleic acid.  There are only four possible bases, so just like computer code is a series of 1’s and 0’s, genetic code is a series of A’s, T’s, G’s, and C’s, each letter standing for a different nitrogen base.  DNA is arranged in two complimentary stands—the famous double helix of Watson and Crick—to create code redundancy like mirrored hard drives that protect your data in case of a crash.

When the genetic code needs to be accessed, a specific portion of the DNA untwists, exposing a segment of code which is copied onto a new strand of messenger RNA (mRNA).  Unlike DNA, RNA is only a single strand of nucleic acid and much less stable.  The mRNA floats into the cell jelly, the cytoplasm, where ribosomes attach and move along the strand, coupling together amino acids as they go.  Every sequence of three bases on the mRNA, known as a codon, codes for a specific amino acid.  For example, GCA codes for alanine, CAA codes for glutamine, and so on.  There are 20 different amino acids, each with its own codon or codons (some have more than one).   Put together according to the sequence of bases on the mRNA, the amino acid chains become a protein.  Out of the trillions of possible amino acid combinations, the proteins formed by your genetic code define the shape of your nose, the length of your bones, the complexion of your skin and everything else that makes you you.  Once the right number of proteins have been made, the mRNA disintegrates into the cytoplasm of the cell.  The process starts again in the nucleus, and a new protein is created as called for by the cell.

What if mRNA could be injected directly into cytoplasm without first being created in the nucleus?  Then the cell’s machinery could create a protein that wasn’t part of the cell’s genetic code.  That’s exactly the hypothesis behind mRNA vaccines.  After the vaccine delivers mRNA into the cytoplasm of muscle cells in the arm, those cells begin forming the protein coded by the mRNA in the vaccine—in the case of COVID vaccines, one of the spike proteins known to exist on the SARS-CoV-2 viral capsule—and those proteins make their way to the surface of the cell where the immune system forms antibodies which are memorized by the body for future use.  How cool is that!

Various companies have been working on mRNA vaccines for over a decade, but none made it to production until the pandemic demanded rapid vaccine development.  Although never been used on a large scale before, mRNA vaccine technology is appealing for several reasons:

  1. Molecular sequencing systems makes creation of mRNA almost as easy as writing a computer script.  
  2. Once sequenced, mRNA can be mass produced easily and cheaply.  
  3. There is no danger from viable pathogens in the vaccine production.  
  4. There are no infectious agents or toxins injected into the vaccine recipient.  
  5. Once the delivery system is perfected, vaccinations for many different pathogens can be created by simply altering the mRNA sequence, making it possible for vaccines to respond quickly to emerging viral variants

Before we anoint mRNA vaccines as our pandemic savior, we should first listen to voices urging caution about this new technology.  For example, in a recent New England Journal of Medicine publicationDr. Mariana Castells and Dr. Elizabeth Phillips note that the incidence of anaphylaxis, a serious, sometimes fatal allergic reaction, associated with the Pfizer SARS-CoV-2 mRNA vaccine is “10 times as high as the incidence reported with all previous vaccines, at approximately 1 in 100,000, as compared 1 in 1,000,000.”  Why?  And moreover, what are our expectations of vaccination?  Do vaccines prevent COVID or simply reduce COVID complications?  How long will immunity last?  Who should NOT get the vaccine?  Answers to these and other questions are not readily apparent, not because of a failure of diligence, but because there has simply not been enough time to collect, compile and analyze the data that will eventually yield answers. 

The Center for Evidence Based Practice at the University of Pennsylvania recently published a review of the adverse effects of mRNA vaccines.  Among their findings are the following:

  1. There are no specific guidelines for use of messenger RNA (mRNA) vaccines or contraindications to mRNA vaccines. 
  2. No large trials of any mRNA vaccine have been completed yet. 
  3. The only evidence on safety of mRNA vaccines comes from small phase I and phase II trials of SARS-CoV-2 vaccines, with follow-up typically less than two months. 
  4. Systemic adverse events such as fatigue, muscle aches, headache, and chills are common 
  5. The rate and severity of adverse events appears to be higher for the second dose of vaccine than for the first. 
  6. Higher vaccine doses appear to increase the rate and severity of adverse events.
  7. Larger trials of SARS-CoV-2 vaccines are in progress, with results expected in mid-2021.
  8. There is not sufficient evidence to support any conclusions on the comparative safety of different mRNA vaccines. 
  9. Direct evidence on the comparative safety of mRNA vaccines and other vaccines is lacking. 

Clearly, mRNA vaccines offer an attractive, promising alternative to other vaccine technology, especially when a new vaccine is needed quickly.  However, it is a new technology associated with risks of the unknown.  Many unanswered questions remain, demanding a sober examination of the evidence for and against vaccine safety.  Since the risk-to-benefit ratio from taking a COVID vaccine varies individually, I urge individual decisions, not collective ones. The Infectious Diseases Society of America recently published a comprehensive FAQ on vaccine safety which you may find to be a valuable great resource for making an individual decision.  

Although paved with good intentions, the early path of new technologies is frequently littered with unintended consequences.  Next time, I will tell a story of good intentions that ended tragically for many.

Categories
2021 COVID-19 Science Vaccine

The Science of COVID

Spoiler alert: This essay contains an unpopular conclusion, and you may disagree.  It’s okay if you do, because you’ll probably be in the company of many of my colleagues who disagree with me too.  Today I’m going to talk about when we can trust science.  To do that, I’m going to pretend to be a scientist and a philosopher.  This is dangerous because, as I have said before, I am neither a scientist nor a philosopher.  Instead, I am a practitioner, applying science to the problems of diagnostic medicine.  As a practitioner, I must know when science is applicable and when it is not.  I know just enough about science and philosophy to be dangerous.

Our experience tells us to trust science, and the explosion of technology during our lifetimes tells us we can.  But science is a process, not a product.  Not everything labelled as science is science.  To understand the difference, let’s consider how science works.

The scientific method begins with a hypothesis.  A hypothesis is just an educated guess about some aspect of reality.  It is proposed by a scientist as a fact of the world, something that can be relied on to be always true within certain conditions.  If the conditions are true, the hypothesis can be used to predict the future and tell us about the past.  

Once formed, the hypothesis is communicated to other scientists, who test the hypothesis by experiment.  The objective of an experiment is not to prove the hypothesis true; rather, the objective of an experiment is to prove the hypothesis false.  If successfully proven false, the hypothesis is rejected.  This is the fate of most hypotheses.  The path of science is littered by the half-truths of discarded hypotheses.  On the other hand, if the hypothesis survives the challenges of repeated experimentation, it becomes elevated by the community of scientists to the status of theory, and its predictions become part of scientific knowledge.  This is a relatively rare phenomenon.  

The falsification objective of the scientific method is a commonly misunderstood aspect of the process, but it is fundamentally important.  It gives science its power over other means of understanding reality, but it also gives science its pace.  It takes time to test hypotheses.  The proof of a hypothesis can be shortened by increasing the number of simultaneous experiments, but only to a point.  Science, like fine wine, requires adequate aging.  

For all its power, the elevation of hypothesis to theory illustrates another weakness of the method: theories are created by scientists.  Scientists are people, and people make mistakes. Scientists have made many.  We can review examples of the most spectacular blunders of scientists later.  The point is that the mistakes of science are the mistakes of people, not fallacies in the method.

So why do we trust science?  Because, despite its flaws and weaknesses, science has increased our understanding of the world exponentially.  But can we be misled by science?  Of course we can, and we are most vulnerable when products labeled as science are not developed with strict adherence to the scientific method.

This brings us to the controversial part.  Most of everything we have learned and developed in the war against COVID-19, including the tests, the treatments, and the vaccines, should not be trusted as science.  In the middle of this emergency, there has not been enough time to fully study the virus and the disease by the scientific method.  Rather, what we have so far are merely hypotheses: the best guesses of the smartest and brightest people in the land.  To be sure, these hypotheses are our best hope in this fight against pandemic, but they should not be labeled science.  There has not been strict adherence to the scientific method.  So, what should we trust, what should we view skeptically, and how can we tell the difference?  We will address these questions next time.